



PTO/SB/08a/b (06-03)

Approved for use through 07/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/901,910-Conf. #7856
				Filing Date	July 11, 2001
				First Named Inventor	Haodong Li
				Art Unit	1635
				Examiner Name	T. Gibbs
				Attorney Docket Number	PF126P2
Sheet	1	of	1		

BEST AVAILABLE COPY

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AH	PAKKANEN et al., "Gene Therapy for Atherosclerosis and Atherosclerosis-Related Diseases," <i>Current Atherosclerosis Rep.</i> , 1:123-130 (1999).	
	AI	DIAZ-SANDOVAL et al., "Gene therapy for cardiovascular angiogenesis," <i>Expert Opin. Biol. Ther.</i> , 3(4):599-616 (2003).	
	AJ	NIKOL et al., "Vascular Gene Therapy - Preclinical and Clinical Experience in Vascular Gene Therapy: Advantages Over Conservative/Standard Therapy," <i>J. Invas. Cardiol.</i> , 13:333-338 (2001).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	9/10/04
-----------------------	--	--------------------	---------